J Cell Mol Med:Sal B靶向TAZ以促进骨生成并通过MEK-ERK通路减少脂肪形成

2019-03-26 不详 网络

丹酚酸B(Sal B)是中草药的主要生物活性成分,最近被确定为骨代谢的介质。本研究旨在探究Sal B调节骨生成和脂肪生成的潜在机制。以MC3T3-E1和3T3-L1为研究模型,探讨Sal B诱导的细胞分化变化。结果显示,不同浓度的Sal B对分化过程中细胞增殖无明显毒性作用。此外,Sal B促进骨生成,但通过增加具有PDZ结合基序(TAZ)的转录共激活因子的表达来抑制脂肪生成。因此,TAZ敲低抵消

丹酚酸B(Sal B)是中草药的主要生物活性成分,最近被确定为骨代谢的介质。本研究旨在探究Sal B调节骨生成和脂肪生成的潜在机制。

以MC3T3-E1和3T3-L1为研究模型,探讨Sal B诱导的细胞分化变化。结果显示,不同浓度的Sal B对分化过程中细胞增殖无明显毒性作用。此外,Sal B促进骨生成,但通过增加具有PDZ结合基序(TAZ)的转录共激活因子的表达来抑制脂肪生成。因此,TAZ敲低抵消了Sal B对细胞分化为成骨细胞或脂肪细胞的影响。值得注意的是,Sal B诱导的TAZ的上调表达被U0126(MEK-ERK抑制剂)而不是LY294002(PI3K-Akt抑制剂)阻断。此外,Sal B增加p-ERK/ERK比率以调节TAZ表达以及细胞分化。

总之,本研究首次表明Sal B靶向TAZ通过激活MEK-ERK信号通路促进成骨和减少脂肪生成,这为Sal B用作治疗骨疾病的潜在治疗剂提供了证据。

原始出处:

Wang N, Li Y, et al., Sal B targets TAZ to facilitate osteogenesis and reduce adipogenesis through MEK-ERK pathway. J Cell Mol Med. 2019 Mar 25. doi: 10.1111/jcmm.14272.

评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1961479, encodeId=ad8d19614e9d3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 20 23:24:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714826, encodeId=4f191e1482666, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Aug 14 15:24:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752124, encodeId=22631e52124d1, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Mon Sep 09 16:24:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943898, encodeId=8e531943898ba, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11525, encryptionId=d2af1152597, topicName=MEK)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Wed Jul 17 09:24:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871200, encodeId=4afe18e1200d6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jan 03 12:24:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609659, encodeId=ab7d1609659cb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 28 06:24:00 CST 2019, time=2019-03-28, status=1, ipAttribution=)]
    2019-10-20 维他命

    #CEL#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1961479, encodeId=ad8d19614e9d3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 20 23:24:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714826, encodeId=4f191e1482666, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Aug 14 15:24:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752124, encodeId=22631e52124d1, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Mon Sep 09 16:24:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943898, encodeId=8e531943898ba, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11525, encryptionId=d2af1152597, topicName=MEK)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Wed Jul 17 09:24:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871200, encodeId=4afe18e1200d6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jan 03 12:24:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609659, encodeId=ab7d1609659cb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 28 06:24:00 CST 2019, time=2019-03-28, status=1, ipAttribution=)]
    2019-08-14 一叶知秋

    #AZ#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1961479, encodeId=ad8d19614e9d3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 20 23:24:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714826, encodeId=4f191e1482666, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Aug 14 15:24:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752124, encodeId=22631e52124d1, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Mon Sep 09 16:24:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943898, encodeId=8e531943898ba, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11525, encryptionId=d2af1152597, topicName=MEK)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Wed Jul 17 09:24:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871200, encodeId=4afe18e1200d6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jan 03 12:24:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609659, encodeId=ab7d1609659cb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 28 06:24:00 CST 2019, time=2019-03-28, status=1, ipAttribution=)]
    2019-09-09 chenlianhui

    #ERK#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1961479, encodeId=ad8d19614e9d3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 20 23:24:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714826, encodeId=4f191e1482666, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Aug 14 15:24:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752124, encodeId=22631e52124d1, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Mon Sep 09 16:24:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943898, encodeId=8e531943898ba, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11525, encryptionId=d2af1152597, topicName=MEK)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Wed Jul 17 09:24:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871200, encodeId=4afe18e1200d6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jan 03 12:24:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609659, encodeId=ab7d1609659cb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 28 06:24:00 CST 2019, time=2019-03-28, status=1, ipAttribution=)]
    2019-07-17 naiwu77

    #MEK#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1961479, encodeId=ad8d19614e9d3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 20 23:24:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714826, encodeId=4f191e1482666, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Aug 14 15:24:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752124, encodeId=22631e52124d1, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Mon Sep 09 16:24:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943898, encodeId=8e531943898ba, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11525, encryptionId=d2af1152597, topicName=MEK)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Wed Jul 17 09:24:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871200, encodeId=4afe18e1200d6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jan 03 12:24:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609659, encodeId=ab7d1609659cb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 28 06:24:00 CST 2019, time=2019-03-28, status=1, ipAttribution=)]
    2020-01-03 zhaozhouchifen

    #Cell#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1961479, encodeId=ad8d19614e9d3, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 20 23:24:00 CST 2019, time=2019-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714826, encodeId=4f191e1482666, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Aug 14 15:24:00 CST 2019, time=2019-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752124, encodeId=22631e52124d1, content=<a href='/topic/show?id=735669505d' target=_blank style='color:#2F92EE;'>#ERK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6950, encryptionId=735669505d, topicName=ERK)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e8a36466835, createdName=chenlianhui, createdTime=Mon Sep 09 16:24:00 CST 2019, time=2019-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1943898, encodeId=8e531943898ba, content=<a href='/topic/show?id=d2af1152597' target=_blank style='color:#2F92EE;'>#MEK#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11525, encryptionId=d2af1152597, topicName=MEK)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b0e350, createdName=naiwu77, createdTime=Wed Jul 17 09:24:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871200, encodeId=4afe18e1200d6, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Jan 03 12:24:00 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609659, encodeId=ab7d1609659cb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 28 06:24:00 CST 2019, time=2019-03-28, status=1, ipAttribution=)]
    2019-03-28 ms3994565386320060

    #Med#

    0